. . . . . . . . . . . . . . . . . . . . "Esopiclone"@en . "(+)-Zopiclone"@en . "Up to 75% of an oral dose of racemic zopiclone is excreted in the urine, primarily as metabolites."@en . . . . "(+)-(5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl-4-methylpiperazine-1-carboxylate"@en . . . "1-Piperazinecarobxylic acid,4-methyl-,(5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester"@en . "138729-47-2"@en . . . . . . . . . . . . . . . . . . . . "approved"@en . . . "6 hours"@en . "Estorra"@en . . . . . "Eszopiclone"@en . "Rapidly absorbed following oral administration"@en . . . . "The mechanism of action of Eszopiclone is not completely understood. It is thought that Eszopiclone acts on the benzodiazepine receptors as an agonist and interacts with GABA-receptor complexes."@en . . "For the treatment of insomnia"@en . "Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic agent (viz., a sedative) used as a treatment for insomnia. Eszopiclone is the active stereoisomer of zopiclone, and belongs to the class of drugs known as cyclopyrrones. Its main selling point is that it is approved by the U.S. Food and Drug Administration for long-term use, unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia."@en . . "Humans and other mammals"@en . . . . . "(+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate"@en . . . . . . . "52-59%"@en . . . . "(S)-Zopiclone"@en . . . "(S)-6-(5-Chloro-2-pyridinyl)- 7-oxo- 6,7-dihydro- 5H-pyrrolo[3,4-b]pyrazin-5-yl- 4-methyl- 1-piperazinecarboxylate"@en . . . . . . . . . " "@en . "Side effects include viral infection, dry mouth, dizziness, hallucinations, infection, rash, and unpleasant taste, with this relationship clearest for unpleasant taste depending on doses."@en . "Marioara MENDELOVICI, Anita LIBERMAN, Alex MAINFELD, Nina FINKELSTEIN, \"METHODS FOR PREPARING ESZOPICLONE CRYSTALLINE FORM A, SUBSTANTIALLY PURE ESZOPICLONE AND OPTICALLY ENRICHED ESZOPICLONE.\" U.S. Patent US20070270590, issued November 22, 2007."@en . . . "Eszopiclone"@en . .